One Complete Response In Platinum Resistant Ovarian Cancer For DMUC5754A
CancerNetwork, the internet home of the journal ONCOLOGY, reported on April 9 from the AACR that the Genentech phase I for its DMUC5754A ( using SGEN ADC technology ) showed one complete response in a patient with platinum resistant ovarian cancer.
"The phase I trial evaluated various doses of DMUC5754A in advanced ovarian and pancreatic cancer patients. DMUC5754A was administered at doses ranging from 0.3 mg/kg to 3.2 mg/kg every 3 weeks. Forty-four patients with advanced, recurrent, platinum-resistant ovarian cancer enrolled; of those, one complete response and four partial responses were reported. All patients who responded were treated with a 2.4 mg/kg dose of the drug and had high MUC16 expression in their tumor cells. Six additional patients had minor responses."
Ricardo's opinion ( however, meaningless or of little value that might be ): Ricardo is impressed with a complete response in this setting. It seems to possibly ( my speculation only ) bode well for an eventual phase II at the 2.4 mg/kg dosing level with patients selected for higher MUC-16 cellular expression.